Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6-11},
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs
Preclinical antitumor efficacy of analogs of XK469 : sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer : results of a phase I study
Phase I and pharmacokinetic study of intraperitoneal topotecan
Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia
A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck
Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)
Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma
Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer
Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan BMS-181339 Breast Cancer Study Group
Topotecan in previously treated advanced urothelial carcinoma : an ECOG phase II trial